Ferring appoints Mirjam Mol-Arts to Executive Committee
in PRESS RELEASE 2020 on
Read more0
0
-
-
Ferring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an amount of CHF 270 million
in PRESS RELEASE 2020 onRead moreFerring Pharmaceuticals successfully launches its inaugural Swiss Franc Bond offering for an…
-
“Standing together against injustice” – a message from Per Falk, President and Chief Science Officer at Ferring
in STATEMENT 2021 onRead more“Standing together against injustice” – a message from Per Falk, President and…
-
Ferring and Igenomix collaborate to advance care in reproductive medicine and maternal health
in PRESS RELEASE 2020 onRead moreFerring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
-
Ferring Statement on the COVID-19 (novel coronavirus disease) Pandemic and Reproductive Medicine
in STATEMENT 2020 onRead moreThe health and safety of our patients, our employees and their families are Ferring’s number one priority. As the situation regarding COVID-19 (novel coronavirus disease) is evolving rapidly, Ferring is committed to following appropriate global, regional and local medical authority guidance to prevent infection spread and to keep patients, our employees and their families safe.
-
Swissmedic approves Carbetocin Ferring for the prevention of postpartum haemorrhage in all births
in PRESS RELEASE 2020 onRead moreFerring Pharmaceuticals today welcomes the Swissmedic approval of Carbetocin Ferring, a heat-stable formulation of carbetocin, for the prevention of excessive bleeding after childbirth following all births, both vaginal and caesarean section. Every year, 14 million women experience excessive bleeding after birth, also known as postpartum haemorrhage…
-
Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660
in PRESS RELEASE 2020 onRead moreToday, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its clinical…
-
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
in PRESS RELEASE 2020 onRead moreRebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy…
-
Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
in PRESS RELEASE 2020 onRead moreFerring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW)…
-
Ferring 70th Anniversary
in TIMELINES onRead moreLorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.